~~<i id='5CD52768B0'><strike id='5CD52768B0'><tt id='5CD52768B0'><pre id='5CD52768B0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

hotspot

author：Wikipedia 2025-09-05 11:29:09 - browse：44

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Eli Lilly reports tirzepatide MASH success during Q4 earnings

hotspot

entertainment

hotspot

Wikipedia

hotspot

CDCWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyour

WSS

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Congress might make insulin pumps more accessible to the blind

Study gives hint on South Asians’ higher risk of cardiovascular disease

Experts study whether long Covid risk adds up with each reinfection

Why are Kaiser Permanente staff considering a strike?

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

hotspot

hotspot

Walensky prepares to leave CDC — and Congress — behind

STAT Virtual Event: Putting AI to the Test

Wildfire smoke exposes gaps in outdoor worker protections

Changes to biosimilar regulatory framework must prioritize patients

How one medical school became remarkably diverse

How Vertex's cystic fibrosis drug is changing patients' lives

Peter Hotez and the public health issue of online harassment

Lasker Awards 2023: Winners in biomedical research

United colonoscopy coverage change 'may cost lives,' doctors say

Artificial intelligence use in health care faces greater scrutiny in 2024

entertainment

Emergency workers more likely to restrain Black patients: study

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Drug for rare kidney disease narrowly misses mark in clinical trial

Abbott's new heart device gets FDA advisory panel nod

Websites selling Wegovy, Zepbound ingredients targeted by FDA

entertainment

hotspot

Wikipedia

hotspot